Follow-on biologics [electronic resource] : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007.Material type: TextSeries: United States. S. hrg: 110-375.Publisher: Washington : U.S. G.P.O., 2008Description: 1 electronic text (iv, 78 pages) : HTML, digital, PDF fileContent type: text Media type: computer Carrier type: online resourceSubject(s): Drug development -- Government policy -- United States | Pharmaceutical biotechnology -- Government policy -- United States | Pharmaceutical biotechnology -- United States -- Patents | Pharmaceutical technology -- Government policy -- United StatesGenre/Form: Patents. Additional physical formats: Follow-on biologics; Follow-on biologicsOnline resources: PDF version: Access document | Text version: Access document
|Item type||Current location||Collection||Call number||Status||Date due||Barcode||Item holds|
|Digital Government Document||Rutgers University Electronic Resource||Electronic Resource||Available|
Paper version available for sale by the Supt. of Docs., U.S. G.P.O.
Title from title screen (viewed on Nov. 17, 2008)
Includes bibliographical references.
Mode of access: Internet from the GPO Access web site.